Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Superluminal Medicines Secures $60 Million in Series B Funding to Advance Obesity Program and Drug Discovery Platform
PRIVATESep 06, 2026•1 day ago
Amount Raised
$60 Million
Round Type
Series B
BostonBiotechnologyHealth Care
Description
Superluminal Medicines has successfully raised an oversubscribed $60 million in Series B financing led by BVF Partners. This funding will enable the company to transition from a discovery-stage platform to a clinical-stage biotechnology firm, helping to advance its lead obesity program into clinical development.
Company Information
Company
Superluminal Medicines
Location
Boston, Massachusetts, United States
About
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
Don't miss Superluminal Medicines's next move
Get an email the moment Superluminal Medicines raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
2 contacts
Predictive Intelligence
Strategic
ML-powered predictions for Superluminal Medicines's next move